Cannabis Bioscience International Holdings Inc.

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities